JP2017512779A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017512779A5 JP2017512779A5 JP2016557602A JP2016557602A JP2017512779A5 JP 2017512779 A5 JP2017512779 A5 JP 2017512779A5 JP 2016557602 A JP2016557602 A JP 2016557602A JP 2016557602 A JP2016557602 A JP 2016557602A JP 2017512779 A5 JP2017512779 A5 JP 2017512779A5
- Authority
- JP
- Japan
- Prior art keywords
- het
- group
- substituents
- alkyl
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- GUSDJDARKXWLBJ-UHFFFAOYSA-N CCBc1cc(O)c2[s]c(C)nc2c1 Chemical compound CCBc1cc(O)c2[s]c(C)nc2c1 GUSDJDARKXWLBJ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461955487P | 2014-03-19 | 2014-03-19 | |
| US61/955,487 | 2014-03-19 | ||
| PCT/EP2015/055237 WO2015140054A1 (en) | 2014-03-19 | 2015-03-12 | Heteroaryl syk inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017512779A JP2017512779A (ja) | 2017-05-25 |
| JP2017512779A5 true JP2017512779A5 (oth) | 2018-04-12 |
| JP6535022B2 JP6535022B2 (ja) | 2019-06-26 |
Family
ID=52706148
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016557952A Active JP6416275B2 (ja) | 2014-03-19 | 2015-03-12 | ヘテロアリールｓｙｋ阻害剤 |
| JP2016557587A Active JP6599884B2 (ja) | 2014-03-19 | 2015-03-12 | 新規なヘテロアリール化合物及び医薬としてのその使用 |
| JP2016557602A Active JP6535022B2 (ja) | 2014-03-19 | 2015-03-12 | ヘテロアリールｓｙｋ阻害剤 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016557952A Active JP6416275B2 (ja) | 2014-03-19 | 2015-03-12 | ヘテロアリールｓｙｋ阻害剤 |
| JP2016557587A Active JP6599884B2 (ja) | 2014-03-19 | 2015-03-12 | 新規なヘテロアリール化合物及び医薬としてのその使用 |
Country Status (32)
| Country | Link |
|---|---|
| US (4) | US9914735B2 (oth) |
| EP (3) | EP3119772B8 (oth) |
| JP (3) | JP6416275B2 (oth) |
| KR (1) | KR102431017B1 (oth) |
| CN (3) | CN106255689B (oth) |
| AP (1) | AP2016009373A0 (oth) |
| AR (1) | AR099785A1 (oth) |
| AU (1) | AU2015233654B2 (oth) |
| CA (1) | CA2942997C (oth) |
| CL (1) | CL2016001963A1 (oth) |
| CY (1) | CY1121937T1 (oth) |
| DK (1) | DK3119772T3 (oth) |
| EA (1) | EA032097B1 (oth) |
| ES (1) | ES2738416T3 (oth) |
| HR (1) | HRP20191364T1 (oth) |
| HU (1) | HUE046061T2 (oth) |
| IL (1) | IL247057B (oth) |
| LT (1) | LT3119772T (oth) |
| ME (1) | ME03472B (oth) |
| MX (1) | MX2016011784A (oth) |
| MY (1) | MY185837A (oth) |
| PE (1) | PE20161427A1 (oth) |
| PH (1) | PH12016501796A1 (oth) |
| PL (1) | PL3119772T3 (oth) |
| PT (1) | PT3119772T (oth) |
| RS (1) | RS59110B1 (oth) |
| SG (1) | SG11201607794QA (oth) |
| SI (1) | SI3119772T1 (oth) |
| TW (1) | TWI680967B (oth) |
| UA (1) | UA119667C2 (oth) |
| UY (1) | UY36037A (oth) |
| WO (3) | WO2015140051A1 (oth) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106255689B (zh) * | 2014-03-19 | 2019-09-17 | 勃林格殷格翰国际有限公司 | 杂芳基syk抑制剂 |
| ES2745284T3 (es) * | 2015-09-11 | 2020-02-28 | Boehringer Ingelheim Int | Heteroarilos sustituidos con pirazolilo y su uso como medicamentos |
| CN108349979B (zh) | 2015-11-02 | 2021-04-09 | 詹森药业有限公司 | [1,2,4]三唑并[1,5-a]嘧啶-7-基化合物 |
| CN105503730B (zh) * | 2015-12-25 | 2018-06-22 | 山东大学 | 吡唑类衍生物及其制备方法与应用 |
| CN109890824B (zh) | 2016-11-02 | 2022-05-24 | 詹森药业有限公司 | 作为pde2抑制剂的[1,2,4]三唑并[1,5-a]嘧啶化合物 |
| MY193511A (en) | 2016-11-02 | 2022-10-17 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors |
| EA039102B1 (ru) | 2016-11-02 | 2021-12-03 | Янссен Фармацевтика Нв | Соединения [1,2,4]триазоло[1,5-a]пиримидина в качестве ингибиторов pde2 |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| MX2020003242A (es) | 2017-09-22 | 2020-09-18 | Jubilant Epipad LLC | Compuestos heterociclicos como inhibidores de pad. |
| AU2018352142B2 (en) | 2017-10-18 | 2022-08-25 | Jubilant Epipad LLC | Imidazo-pyridine compounds as PAD inhibitors |
| KR20200085836A (ko) | 2017-11-06 | 2020-07-15 | 주빌런트 프로델 엘엘씨 | Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체 |
| BR112020010322A2 (pt) | 2017-11-24 | 2020-11-17 | Jubilant Episcribe Llc | composto da fórmula i; composto da fórmula ia; composto da fórmula ib; processo de preparação de compostos da fórmula i; composição farmacêutica; método para o tratamento e/ou prevenção de várias doenças; uso dos compostos; método para o tratamento de câncer; e método para o tratamento e/ou prevenção de uma afecção mediada por prmt5 ou um distúrbio proliferativo ou câncer |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| SG11202008950PA (en) | 2018-03-13 | 2020-10-29 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| TWI721623B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| TW202136261A (zh) | 2018-10-31 | 2021-10-01 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| JP7623943B2 (ja) | 2018-11-30 | 2025-01-29 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| US11633399B2 (en) | 2018-12-25 | 2023-04-25 | Sol-Gel Technologies Ltd. | Treatment of skin disorders with compositions comprising an EGFR inhibitor |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| BR112021026517A2 (pt) | 2019-06-28 | 2022-05-10 | Kymera Therapeutics Inc | Degradadores de irak e usos dos mesmos |
| WO2020264490A1 (en) * | 2019-06-28 | 2020-12-30 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| US12551564B2 (en) | 2019-12-10 | 2026-02-17 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| WO2021127190A1 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2021127283A2 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| US20220213086A1 (en) * | 2020-12-25 | 2022-07-07 | Eternity Bioscience Inc. | Azole compounds as irak inhibitors, preparation methods and medicinal uses thereof |
| PH12023500015A1 (en) | 2020-12-30 | 2024-03-11 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2022174268A1 (en) | 2021-02-15 | 2022-08-18 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| CN116867494A (zh) | 2021-02-15 | 2023-10-10 | 凯麦拉医疗公司 | Irak4降解剂和其用途 |
| KR20220138655A (ko) * | 2021-04-06 | 2022-10-13 | 주식회사 온코크로스 | 신장 질환의 예방 또는 치료용 화합물 |
| KR20220138654A (ko) * | 2021-04-06 | 2022-10-13 | 주식회사 온코크로스 | 당뇨병의 예방 또는 치료용 화합물 |
| US12187744B2 (en) | 2021-10-29 | 2025-01-07 | Kymera Therapeutics, Inc. | IRAK4 degraders and synthesis thereof |
| EP4472967A4 (en) | 2022-01-31 | 2026-04-15 | Kymera Therapeutics Inc | Iraqi Degradation Agents and Their Uses |
| CN115215803B (zh) * | 2022-09-19 | 2022-12-30 | 苏州美诺医药科技有限公司 | 一种4-卤代-1-(二氟甲基)-1h-咪唑的制备方法 |
| EP4602043A1 (en) | 2022-10-14 | 2025-08-20 | Genesis Therapeutics, Inc. | 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer |
| CN116836162B (zh) * | 2023-05-24 | 2025-09-05 | 南方医科大学 | 吡唑[4,3-c]吡啶类化合物或其药学上可接受的盐及其应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4260759A (en) | 1969-04-14 | 1981-04-07 | Schering-Corporation | Process for preparing 1-aminonaphthyridines |
| US3928367A (en) | 1969-04-14 | 1975-12-23 | Schering Corp | 1-Amino naphthyridines |
| US4017500A (en) | 1973-07-16 | 1977-04-12 | Schering Corporation | Certain 8-amino-1,7-naphthyridines |
| FR2260330A1 (en) | 1974-02-07 | 1975-09-05 | Innothera Lab Sa | Pyridoxine N-oxy nicotinate - hypolipaemiant and hypocholesterolemiant of good therapeutic index |
| US4115395A (en) | 1975-11-12 | 1978-09-19 | Schering Corporation | 1-Aminonaphthyridines |
| ATE404539T1 (de) | 1997-10-02 | 2008-08-15 | Eisai R&D Man Co Ltd | Kondensierte pyridinderivate |
| JP2003520042A (ja) | 2000-01-24 | 2003-07-02 | アイシス・ファーマシューティカルス・インコーポレーテッド | 誘導性一酸化窒素シンターゼ発現のアンチセンスモジュレーション |
| GB0004153D0 (en) | 2000-02-23 | 2000-04-12 | Astrazeneca Uk Ltd | Novel use |
| JP2001302667A (ja) | 2000-04-28 | 2001-10-31 | Bayer Ag | イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体 |
| CN100519558C (zh) | 2000-10-12 | 2009-07-29 | 贝林格尔英格海姆法玛两合公司 | 结晶单水合物、其制备方法及其在制备药物组合中的用途 |
| AR035700A1 (es) | 2001-05-08 | 2004-06-23 | Astrazeneca Ab | Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados |
| CZ302786B6 (cs) | 2001-06-22 | 2011-11-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Krystalický bezvodý tiotropiumbromid, zpusob jeho výroby a jeho použití pro výrobu léciva pro lécbu asthmatu |
| US20030158195A1 (en) | 2001-12-21 | 2003-08-21 | Cywin Charles L. | 1,6 naphthyridines useful as inhibitors of SYK kinase |
| SE0203304D0 (sv) | 2002-11-07 | 2002-11-07 | Astrazeneca Ab | Novel Coumpounds |
| US20080119515A1 (en) | 2003-03-10 | 2008-05-22 | M Arshad Siddiqui | Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis |
| CN1784229A (zh) * | 2003-03-10 | 2006-06-07 | 先灵公司 | 杂环激酶抑制剂:使用方法与合成 |
| WO2006038041A1 (en) | 2004-10-08 | 2006-04-13 | Merck Sharp & Dohme Limited | Besylate salts of six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain |
| US8703804B2 (en) * | 2006-03-26 | 2014-04-22 | Uti Limited Partnership | Ryanodine receptor inhibitors and methods relating thereto |
| DE102007012645A1 (de) | 2007-03-16 | 2008-09-18 | Bayer Healthcare Ag | Substituierte Imidazo- und Triazolopyrimidine |
| JP5754568B2 (ja) | 2008-08-05 | 2015-07-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ４−ジメチルアミノ−フェニルで置換されているナフチリジン、及び医薬としてのその使用 |
| JP2011529932A (ja) * | 2008-08-05 | 2011-12-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換ナフチリジン及び医薬としてのその使用 |
| TWI453207B (zh) * | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| NZ600857A (en) * | 2010-01-29 | 2014-06-27 | Boehringer Ingelheim Int | Substituted naphthyridines and their use as syk kinase inhibitors |
| US20140005188A1 (en) | 2011-03-11 | 2014-01-02 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
| EP2691399B1 (en) | 2011-03-28 | 2016-07-13 | F.Hoffmann-La Roche Ag | Thiazolopyrimidine compounds |
| WO2012167423A1 (en) | 2011-06-08 | 2012-12-13 | Hutchison Medipharma Limited | Substituted pyridopyrazines as novel syk inhibitors |
| CN103827090B (zh) * | 2011-07-26 | 2016-04-20 | 勃林格殷格翰国际有限公司 | 取代的喹啉及其作为药物的用途 |
| WO2013047813A1 (ja) * | 2011-09-30 | 2013-04-04 | 大鵬薬品工業株式会社 | １，２，４－トリアジン－６－カルボキサミド誘導体 |
| CN104540830A (zh) * | 2012-06-07 | 2015-04-22 | 霍夫曼-拉罗奇有限公司 | 端锚聚合酶的吡唑并嘧啶酮和吡唑并吡啶酮抑制剂 |
| US20140309233A1 (en) | 2012-12-18 | 2014-10-16 | Hulow, Llc | Syk kinase inhibitors as treatment for malaria |
| NZ715747A (en) * | 2013-07-31 | 2017-03-31 | Gilead Sciences Inc | Syk inhibitors |
| CN106255689B (zh) * | 2014-03-19 | 2019-09-17 | 勃林格殷格翰国际有限公司 | 杂芳基syk抑制剂 |
| TW201617074A (zh) | 2014-07-14 | 2016-05-16 | 吉李德科學股份有限公司 | Ｓｙｋ（脾酪胺酸激酶）抑制劑 |
| ES2745284T3 (es) | 2015-09-11 | 2020-02-28 | Boehringer Ingelheim Int | Heteroarilos sustituidos con pirazolilo y su uso como medicamentos |
-
2015
- 2015-03-12 CN CN201580013694.5A patent/CN106255689B/zh active Active
- 2015-03-12 EP EP15711451.3A patent/EP3119772B8/en active Active
- 2015-03-12 DK DK15711451.3T patent/DK3119772T3/da active
- 2015-03-12 WO PCT/EP2015/055228 patent/WO2015140051A1/en not_active Ceased
- 2015-03-12 PT PT15711451T patent/PT3119772T/pt unknown
- 2015-03-12 PE PE2016001619A patent/PE20161427A1/es unknown
- 2015-03-12 CN CN201910255696.5A patent/CN110183440B/zh active Active
- 2015-03-12 JP JP2016557952A patent/JP6416275B2/ja active Active
- 2015-03-12 EP EP15711453.9A patent/EP3119766B1/en active Active
- 2015-03-12 SI SI201530823T patent/SI3119772T1/sl unknown
- 2015-03-12 US US15/027,518 patent/US9914735B2/en active Active
- 2015-03-12 UA UAA201610495A patent/UA119667C2/uk unknown
- 2015-03-12 US US15/125,599 patent/US20170008896A1/en not_active Abandoned
- 2015-03-12 HR HRP20191364 patent/HRP20191364T1/hr unknown
- 2015-03-12 WO PCT/EP2015/055242 patent/WO2015140055A1/en not_active Ceased
- 2015-03-12 LT LTEP15711451.3T patent/LT3119772T/lt unknown
- 2015-03-12 PL PL15711451T patent/PL3119772T3/pl unknown
- 2015-03-12 MX MX2016011784A patent/MX2016011784A/es active IP Right Grant
- 2015-03-12 EP EP15711452.1A patent/EP3119765B1/en active Active
- 2015-03-12 ES ES15711451T patent/ES2738416T3/es active Active
- 2015-03-12 JP JP2016557587A patent/JP6599884B2/ja active Active
- 2015-03-12 HU HUE15711451A patent/HUE046061T2/hu unknown
- 2015-03-12 WO PCT/EP2015/055237 patent/WO2015140054A1/en not_active Ceased
- 2015-03-12 AU AU2015233654A patent/AU2015233654B2/en active Active
- 2015-03-12 SG SG11201607794QA patent/SG11201607794QA/en unknown
- 2015-03-12 CA CA2942997A patent/CA2942997C/en active Active
- 2015-03-12 JP JP2016557602A patent/JP6535022B2/ja active Active
- 2015-03-12 MY MYPI2016001423A patent/MY185837A/en unknown
- 2015-03-12 CN CN201910890873.7A patent/CN110713489B/zh active Active
- 2015-03-12 EA EA201691864A patent/EA032097B1/ru not_active IP Right Cessation
- 2015-03-12 KR KR1020167029202A patent/KR102431017B1/ko active Active
- 2015-03-12 ME MEP-2019-222A patent/ME03472B/me unknown
- 2015-03-12 AP AP2016009373A patent/AP2016009373A0/en unknown
- 2015-03-12 RS RS20191047A patent/RS59110B1/sr unknown
- 2015-03-18 TW TW104108672A patent/TWI680967B/zh active
- 2015-03-18 AR ARP150100815A patent/AR099785A1/es active IP Right Grant
- 2015-03-19 UY UY0001036037A patent/UY36037A/es unknown
-
2016
- 2016-08-02 IL IL24705716A patent/IL247057B/en active IP Right Grant
- 2016-08-04 CL CL2016001963A patent/CL2016001963A1/es unknown
- 2016-09-14 PH PH12016501796A patent/PH12016501796A1/en unknown
-
2017
- 2017-11-20 US US15/817,435 patent/US20180072744A1/en not_active Abandoned
-
2019
- 2019-08-08 US US16/535,337 patent/US10947243B2/en active Active
- 2019-08-20 CY CY20191100888T patent/CY1121937T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017512779A5 (oth) | ||
| EP4139286B1 (en) | Substituted aminothiazoles as dgkzeta inhibitors for immune activation | |
| AU2019201480B2 (en) | Heterocyclic amides as kinase inhibitors | |
| JP2016516699A5 (oth) | ||
| JP2017502940A5 (oth) | ||
| HRP20191364T1 (hr) | Sik-inhibitori tipa heteroarila | |
| JP2014525420A5 (oth) | ||
| JP2016536364A5 (oth) | ||
| JP2019524883A5 (oth) | ||
| AU2018236691A1 (en) | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| JP2016507581A5 (oth) | ||
| JP2011507854A5 (oth) | ||
| JP2012532112A5 (oth) | ||
| IL257392A (en) | The troarils are converted to pyrazolil and their use as drugs | |
| JP2017071634A5 (oth) | ||
| JP2016514719A5 (oth) | ||
| JP2016537369A5 (oth) | ||
| JP2018519323A5 (oth) | ||
| MY192109A (en) | Aminopyrimidinyl compounds as jak inhibitors | |
| EA007933B1 (ru) | 2,4,5-тризамещенные производные тиазолила и их противовоспалительная активность | |
| JP2016532715A5 (oth) | ||
| JP2014510147A5 (oth) | ||
| JP2013542267A5 (oth) | ||
| JP2010540602A5 (oth) | ||
| JP2016503785A5 (oth) |